Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, Ito T, Kambarov Y, Llorca PM, Oliveira-Maia AJ, Messer T, Mulhern-Haughey S, Rive B, von Holt C, Young AH, Godinov Y; ESCAPE-TRD Investigators. Reif A, et al. Among authors: mulhern haughey s. N Engl J Med. 2023 Oct 5;389(14):1298-1309. doi: 10.1056/NEJMoa2304145. N Engl J Med. 2023. PMID: 37792613 Free article. Clinical Trial.
Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization.
Heerlein K, De Giorgi S, Degraeve G, Frodl T, Hagedoorn W, Oliveira-Maia AJ, Otte C, Perez Sola V, Rathod S, Rosso G, Sierra P, Vita A, Morrens J, Rive B, Mulhern Haughey S, Kambarov Y, Young AH. Heerlein K, et al. Among authors: mulhern haughey s. J Affect Disord. 2022 Feb 1;298(Pt A):442-450. doi: 10.1016/j.jad.2021.11.004. Epub 2021 Nov 4. J Affect Disord. 2022. PMID: 34742998 Free article.
Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study.
Oliveira-Maia AJ, Rive B, Morrens J, Godinov Y, Cabrieto J, Perualila N, Mulhern-Haughey S. Oliveira-Maia AJ, et al. Among authors: mulhern haughey s. Front Psychiatry. 2023 Oct 31;14:1250987. doi: 10.3389/fpsyt.2023.1250987. eCollection 2023. Front Psychiatry. 2023. PMID: 38025416 Free PMC article.
ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry.
Oliveira-Maia AJ, Morrens J, Rive B, Godinov Y, Cabrieto J, Perualila N, Barbreau S, Mulhern-Haughey S. Oliveira-Maia AJ, et al. Among authors: mulhern haughey s. Front Psychiatry. 2023 Oct 31;14:1250980. doi: 10.3389/fpsyt.2023.1250980. eCollection 2023. Front Psychiatry. 2023. PMID: 38025433 Free PMC article.
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.
Young AH, Llorca PM, Fagiolini A, Falkai P, Cardoner N, Nielsen RE, Blomqvist O, Godinov Y, Rive B, Diels J, Mulhern-Haughey S, Reif A. Young AH, et al. Among authors: mulhern haughey s. Br J Psychiatry. 2024 Dec 2:1-7. doi: 10.1192/bjp.2024.124. Online ahead of print. Br J Psychiatry. 2024. PMID: 39618237
11 results